Baker A, Beed S, Fenwick J, Kjerulf M, Bell H, Logier S, Shepherd J. Number of deaths by neurological criteria, and organ and tissue donation rates at three critical care centres in Canada: [Le nombre de morts salon des criteres neurologiques et les taux de dons d'organes et de tissue dans trois centres de soins intensifs au Canada]. Can J Anaesth 53:722-726, 2006.
Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108: 88-96, 2006.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielson JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23):2408-17, 2006.
Foltz LM, Song KW, Connors JM. Hodgkin’s Lymphoma in Adolescents. Journal of Clinical Oncology 24: 2520-26, 2006.
Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH, Hogge DE. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 47: 1245-1252, 2006.
Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12: 1284-1291, 2006.
Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant 12: 480-489, 2006.
Laneuville PJ, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy D-C, Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia (CCGM-CML). Curr Onc 13: 1-20, 2006.
Li S, Ferguson MJ, Hawkins CJ, Smith C, Elwood N. Human telomerase reverse transcriptase protects hematopoietic progenitor TF-1 cells from death and quiescence induced by cytokine withdrawal. Leukemia 20: 1270-1278, 2006.
Lin Y, Bruyere H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170: 16-23, 2006.
Savoie ML, Nevill TJ, Song KW, Forrest DL, Hogge DE, Nantel SH,Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 17: 763-768, 2006.
Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133: 634-637, 2006.
Song KW, Barnett MJ, Gascoyne RD, Chanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favourable outcomes. Annals of Oncology, Dec 8, 2006, epub.
Spidlen J, Gentleman RC, Haaland P, Langille M, LeMeur N, Ochs MF, Schmitt C, Smith CA, Treister A, Brinkman R. Bioinformatics data standards for flow cytometry. OMICS 10: 209-214, 2006.
Walsh, CJ., Luer VA, Bodine AB, Smith CA, Cox HL, Noyes DR and Gasparetto M. Elasmobranch immune cells as a source of novel tumor cell inhibitors: Implications for public health. Integr. Comp. Biol. 46:1072-1081, 2006.
Yalcintepe I, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108(10): 3530-7, 2006.
